Comment on “combination treatment including targeted therapy for advanced hepatocellular carcinoma”

We read with great interest the article by Lin et al. (1) entitled “Combination treatment including targeted therapy for advanced hepatocellular carcinoma”, published in the Oncotarget. The authors have collected and reviewed the results of clinical trials concerning combination therapy based on molecular targeted agents (MTAs) within advanced hepatocellular carcinoma (HCC). In this article, combinative strategies include chemotherapy plus targeted therapy, diverse MTAs combination, TACE/TAE plus targeted therapy as well other combinative treatments. According to the summarized results from this paper, while various combinative treatments have been explored in clinical practice, few satisfied therapeutic effects obtained in the management of advanced HCC.